Christina Coughlin
Algemeen Directeur bij AVACTA GROUP PLC
Actieve functies van Christina Coughlin
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
AVACTA GROUP PLC | Directeur/Bestuurslid | 21-03-2022 | - |
Algemeen Directeur | 01-05-2024 | - | |
Hoofd Techniek/Wetenschap/O&O | 01-02-2024 | 01-05-2024 |
Loopbaan van Christina Coughlin
Eerdere bekende functies van Christina Coughlin
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Cytoimmune Therapeutics, Inc.
Cytoimmune Therapeutics, Inc. BiotechnologyHealth Technology Cytoimmune Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2017 and based in Toa, Japan. The American company is focused on developing a pipeline of NK cell therapies for various types of cancer, including lung cancer, acute myeloid leukemia, solid tumors, and multiple myeloma. The private company's lead product, Cyto-102, is a track-NK cell therapy that aims to enter clinical trials in combination with atezolizumab for non-small cell lung cancer in 2022. Cytoimmune Therapeutics also offers cell therapy development and clinical manufacturing services to biotechnology companies and academia. The company's state-of-the-art clinical cell manufacturing facility is custom-built to support the development and commercialization of cutting-edge T cell or NK cell therapies. The company was founded in 2017 by Michael A. Caligiuri, William Michael Rosellini, and Jianhua Yu, Ph.D. José Eduardo Vidal has been the CEO of the company since 2021. | Directeur/Bestuurslid | 10-11-2021 | 18-07-2023 |
Algemeen Directeur | 10-11-2021 | 18-07-2023 | |
RUBIUS THERAPEUTICS | Hoofd Techniek/Wetenschap/O&O | 06-01-2020 | 12-11-2021 |
Tmunity Therapeutics, Inc.
Tmunity Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tmunity Therapeutics, Inc. develops novel products that free the immunological potential of T cells to treat disease indications. It develops novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms. The company was founded by Carl H. June, Anne Chew, Bruce Levine, Yangbing Zhao, James L. Riley and Bruce Blazar and is headquartered in Philadelphia, PA. | Hoofd Techniek/Wetenschap/O&O | 01-07-2018 | 01-11-2019 |
IMMUNOCORE HOLDINGS PLC | Hoofd Techniek/Wetenschap/O&O | 01-04-2015 | 01-07-2018 |
Opleiding van Christina Coughlin
Temple University (Pennsylvania) | Undergraduate Degree |
University of Pennsylvania | Doctorate Degree |
Statistieken
Internationaal
Verenigde Staten | 6 |
Verenigd Koninkrijk | 3 |
Operationeel
Chief Tech/Sci/R&D Officer | 4 |
Director/Board Member | 2 |
Chief Executive Officer | 2 |
Sectoraal
Health Technology | 4 |
Consumer Services | 3 |
Commercial Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
IMMUNOCORE HOLDINGS PLC | Health Technology |
AVACTA GROUP PLC | Commercial Services |
Bedrijven in privébezit | 3 |
---|---|
Rubius Therapeutics, Inc.
Rubius Therapeutics, Inc. BiotechnologyHealth Technology Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines. It provides medicine for cancer, autoimmune diseases, hemophilia, infectious and metabolic diseases. The company was founded on April 26, 2013 and is headquartered in Foxboro, MA. | Health Technology |
Tmunity Therapeutics, Inc.
Tmunity Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tmunity Therapeutics, Inc. develops novel products that free the immunological potential of T cells to treat disease indications. It develops novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms. The company was founded by Carl H. June, Anne Chew, Bruce Levine, Yangbing Zhao, James L. Riley and Bruce Blazar and is headquartered in Philadelphia, PA. | Commercial Services |
Cytoimmune Therapeutics, Inc.
Cytoimmune Therapeutics, Inc. BiotechnologyHealth Technology Cytoimmune Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2017 and based in Toa, Japan. The American company is focused on developing a pipeline of NK cell therapies for various types of cancer, including lung cancer, acute myeloid leukemia, solid tumors, and multiple myeloma. The private company's lead product, Cyto-102, is a track-NK cell therapy that aims to enter clinical trials in combination with atezolizumab for non-small cell lung cancer in 2022. Cytoimmune Therapeutics also offers cell therapy development and clinical manufacturing services to biotechnology companies and academia. The company's state-of-the-art clinical cell manufacturing facility is custom-built to support the development and commercialization of cutting-edge T cell or NK cell therapies. The company was founded in 2017 by Michael A. Caligiuri, William Michael Rosellini, and Jianhua Yu, Ph.D. José Eduardo Vidal has been the CEO of the company since 2021. | Health Technology |
- Beurs
- Insiders
- Christina Coughlin
- Ervaring